Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform
Initial goal to determine treatment efficacy of iTeos’ immuno-oncology drug candidates Option for iTeos to license Cristal’s proprietary nanotechnology platform for development of up to three immuno-oncology therapeutic candidates Maastricht, The Netherlands and Gosselies, Belgium – December 7th, 2016 – Cristal Therapeutics, a Dutch privately-held life sciences company developing novel nanomedicines against cancer and other […]
